Chicago—The combination of atezolizumab (Tecentriq, Genentech) and bevacizumab (Avastin, Genentech) appears to be a promising first-line treatment for patients with metastatic renal cell carcinoma (mRCC), according to Phase II study results presented at the 2017 annual meeting of the American Society for Clinical Oncology (abstract 4505).
Although vascular endothelial growth factor (VEGF) inhibitors are effective, many patients with mRCC develop resistance, often within a year.
“While